BRIEF-Lilly's Cyramza meets Primary Endpoint in gastric cancer study By: Reuters: Company News December 08, 2017 at 17:38 PM EST * LILLY REPORTS TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 STUDY IN FIRST-LINE ADVANCED GASTRIC CANCER Read More >> Related Stocks: Eli Lilly